Skip to main content

Familial Cold Autoinflammatory Syndrome

1
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
1 program
1
DFV890Phase 21 trial
Active Trials
NCT04868968Completed4Est. May 2023
Novartis
NovartisBASEL, Switzerland
1 program
DFV890PHASE_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SandozDFV890

Clinical Trials (1)

Total enrollment: 4 patients across 1 trials

Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)

Start: Sep 2021Est. completion: May 20234 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.